Taking Science to Market at Entrepreneurial Speed

Likarda LLC is a world-class, cutting-edge biotech research laboratory for science entrepreneurs, partners for bio consortiums, and contract research organizations (CRO). As a CRO outsourcing service, we combine comprehensive early-phase discovery research with consultative and analytical services so that you can move ahead in the drug discovery process with confidence, efficiency, and success at an affordable rate.

We focus on bringing to market disruptive technologies that improve health-care outcomes and lower costs for pets and people alike. Likarda uses our proprietary cell culture system, the CC Microplate™, to create three-dimensional cell clusters, or miniaturized organs. Our CC Microplate has applications in markets ranging from drug discovery and development to cell-based transplantation and regenerative medicine. For instance, pharmaceutical companies can test new drug compounds on our human 3D cell clusters, providing a better prediction of how the drugs will work in the body.

Science entrepreneurs in their own right, Likarda’s founders, Lisa Stehno-Bittel, PhD, and Karthik Ramachandran, PhD, developed these innovations while employed as researchers at the University of Kansas Medical Center where they focused on discovering and providing next-generation treatments for diabetes. The technology consists of our proprietary and patented CC Microplate plate and manufacturing process.

Creators of the Kanslet™
Today, Likarda is the leading regenerative medicine company for companion animals. We have discovered—and are commercializing—a better way to manage diabetes in dogs and cats. By harvesting islet cells, the body’s insulin-producing cells, from a donor pancreas then essentially building a better islet, called a Kanslet™ or a reaggregated islet, and transplanting those cells into a dog with diabetes, Likarda will allow veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.

In 2012, the founders discovered the power of Kanslets for secondary drug testing and have published multiple studies in support of the technology. Shortly after making this discovery, the two scientists established Likarda and the intellectual property and patents were exclusively licensed from the University of Kansas.

We partner with our clients, be they pharmaceutical companies or science entrepreneurs who need CRO outsourcing services, but couldn’t otherwise gain access to early-phase discovery research, to champion high-quality, cutting-edge products and services. We constantly seek to create the next improved version.

Likarda is the culmination of visionary leadership, science that is just as artistic as academic, and a compelling urge to do what’s right. To accomplish this, we have well-defined, long-range goals with the added opportunity for flexibility and growth.